Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2009 Sep 3;114(10):2051-9.
doi: 10.1182/blood-2008-10-184143. Epub 2009 Jul 7.

A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425

Cindy L Schwartz  1 , Louis S Constine, Doojduen Villaluna, Wendy B London, Robert E Hutchison, Richard Sposto, Steven E Lipshultz, Charles S Turner, Pedro A deAlarcon, Allen Chauvenet
Affiliations
Clinical Trial

A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425

Cindy L Schwartz et al. Blood. .

Erratum in

Abstract

Current treatment strategies for Hodgkin lymphoma result in excellent survival but often confer significant long-term toxicity. We designed ABVE-PC (doxorubicin, bleomycin, vincristine, etoposide, prednisone, cyclophosphamide) to (1) enhance treatment efficacy by dose-dense drug delivery and (2) reduce risk of long-term sequelae by response-based reduction of cumulative chemotherapy. Efficient induction of early response by dose-dense drug delivery supported an early-response-adapted therapeutic paradigm. The 216 eligible patients were younger than 22 years with intermediate- or high-risk Hodgkin lymphoma. ABVE-PC was administered every 21 days. Rapid early responders (RERs) to 3 ABVE-PC cycles received 21 Gy radiation to involved regions; RER was documented in 63% of patients. Slow early responders received 2 additional ABVE-PC cycles before 21 Gy radiation. Five-year event-free-survival was 84%: 86% for the RER and 83% for the slow early responders (P = .85). Only 1% of patients had progressive disease. Five-year overall survival was 95%. With this regimen, cumulative doses of alkylators, anthracyclines, and epipodophyllotoxins are below thresholds usually associated with significant long-term toxicity. ABVE-PC is a dose-dense regimen that provides outstanding event-free survival/overall survival with short duration, early-response-adapted therapy.

Trial registration: ClinicalTrials.gov NCT00005578.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Treatment assignments and numbers of patients included in the analysis.
Figure 2
Figure 2
Event-free and overall survival. (A) Overall EFS and OS curves for 216 HL patients treated on P9425. (B) EFS curves for intermediate-risk versus high-risk patients (P = .87). (C) EFS curves for rapid early responders versus slow early responders (P = .81).
See this image and copyright information in PMC

References

    1. DeVita VT, Jr, Simon RM, Hubbard SM, et al. Curability of advanced Hodgkin's disease with chemotherapy: long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med. 1980;92(5):587–595. - PubMed
    1. Santoro A, Bonadonna G, Bonfante V, et al. Alternating drug combinations in the treatment of advanced Hodgkin's disease. N Engl J Med. 1982;306(13):770–775. - PubMed
    1. Longo DL, Young RC, Wesley M, et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol. 1986;4(9):1295–1306. - PubMed
    1. Van Rijswijk RE, Haanen C, Dekker AW, et al. Dose intensity of MOPP chemotherapy and survival in Hodgkin's disease. J Clin Oncol. 1989;7(12):1776–1782. - PubMed
    1. Carde P, MacKintosh FR, Rosenberg SA. A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. J Clin Oncol. 1983;1(2):146–153. - PubMed

Publication types

Associated data